avb6 integrin inhibitor + lysosomal degrader

in vitro degradation, Ph. I completed, discont.

derived from prior integrin inhibitors

J. Pharmacol. Exp. Ther., Jan. 26, 2021

GlaxoSmithKline, Stevenage, UK

The GSK αvβ6 integrin inhibitor, “compound 1,” or GSK 3008348 is a previously reported IPF clinical candidate that is a picomolar binder to αvβ6 with slow dissociation kinetics. The…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks